ArticleClinical and experimental pediatrics2020
Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2.
Article in Clinical and experimental pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.PloS one · 2021Pooled it
- A new immunological paradigm for diseases: the protein-homeostasis-system hypothesis.Frontiers in immunology · 2026Review
- Common immunopathogenesis of central nervous system diseases: the protein-homeostasis-system hypothesis.Cell & bioscience · 2022Review
- Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease.Clinical and experimental pediatrics · 2022Article
- Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.International journal of biological sciences · 2022Review
- Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19.ACS biomaterials science & engineering · 2021Review
- Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.Pediatric rheumatology online journal · 2021Review
- Immunity, endothelial injury and complement-induced coagulopathy in COVID-19.Nature reviews. Nephrology · 2021Review
- Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.Journal of translational autoimmunity · 2021Review
- COVID-19-Associated Coagulopathy and Inflammatory Response: What Do We Know Already and What Are the Knowledge Gaps?Anesthesia and analgesia · 2020Review
- Overview of management of children with COVID-19.Clinical and experimental pediatrics · 2020Article
- Immunopathogenesis of COVID-19 and early immunomodulators.Clinical and experimental pediatrics · 2020Article
- Immunology of COVID-19: Current State of the Science.Immunity · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.